Latest Press Releases

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. JOURNAVX is an effective, well-tolerated medicine without evidence of addictive potential indicated for use across all types of moderate-to-severe acute pain.

Beckman Coulter Diagnostics, a global leader in clinical diagnostics, announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Beckman Coulter's Access p‑Tau217/β-Amyloid 1-42 plasma ratio. This blood test is designed to aid healthcare providers identify patients with amyloid pathology associated with Alzheimer's disease.

Young Pharmaceuticals, Inc., a leading provider of physician-dispensed skincare products, announces an exclusive distribution agreement with LAC2βiome S.r.l., a maker of microbial based product solutions in Milan, Italy.

Vetter, a globally operating Contract Development and Manufacturing Organization (CDMO), has announced the development and upcoming launch of the new version of its proprietary V-OVS® syringe closure system.

Yamaha Motor Co., Ltd. (Tokyo: 7272) announced that it will exhibit the CELL HANDLER™ 2, a cell picking and imaging system, at marking the product's first overseas exhibition.

SN BioScience announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial. This achievement follows the designation of SNB-101 as an orphan drug for small cell lung cancer in 2023 and its Fast Track designation in 2024.

CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, announced that Jan Case has joined the Company as Chief Operating Officer.

Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90° articulation capability, has been approved for market release in China by the National Medical Products Administration (NMPA).

Orthogon Therapeutics, a developer of novel antiviral medicines, announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients.

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced that its Life Sciences subsidiary, GenScript, has introduced a next generation DNA purification platform: